Interní Med. 2013; 15(6-7): 220-224

Diabetes and heart failure

doc.MUDr.Jozef Bulas, CSc., prof.MUDr.Ján Murín, CSc.
I. interná klinika, LF UK a UN Bratislava

Diabetes mellitus and heart failure are nowadays both diseases having an epidemic characteristics. Diabetes seems to be an engine of

heart failure development. More severe heart failure forms show more frequently the presence of diabetes. This is true for both systolic

and diastolic heart failure types. In the pathophysiology of heart failure in diabetics there is an influence of myocardial ischaemia, of

meta bolic (lipidic and diabetic) serum changes and of diabetic cardiomyopathy. Also activation of the renin- angiotensin-aldosterone

system is important: mainly the alternative pathway where enhanced activity of ACE-2 enzyme seems to be present. The authors present

here dinical signs of heart failure and also the management of heart failure in diabetics. He discusses the problem of strict versus normal

control of serum glycaemia, and also the pharmacological treatment of diabetes, mostly from the safety point of view. The benefitial drug

is metformin, we can also use the sulphonylurea derivateves, insulin, and very promissing drugs are incretines. The occurence of type

2 diabetes and heart failure increases and will increase. It is therefore necessary to search for diabetes, to do preventive measures and

support healthy way of life as the pre vention is here better than treatment.

Keywords: diabetes mellitus, heart failure, diabetic cardiomyopathy, antidiabetics

Published: July 15, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bulas J, Murín J. Diabetes and heart failure. Interní Med. 2013;15(6-7):220-224.
Download citation

References

  1. Mokáň M, Galajda P, Prídavková D, et al. Prevalencia diabetes mellitus a metabolického syndrómu na Slovensku. Diabetes a obezita 2006; 12: 10-17.
  2. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974; 34: 29-34. Go to original source... Go to PubMed...
  3. Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the Cardiovascular health study. J Am Coll Cardiol 2000; 35: 1628-1637. Go to original source... Go to PubMed...
  4. Nichols GA, Hillier TA, Erbey JR, et al. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001; 24: 1614-1619. Go to original source... Go to PubMed...
  5. Arnold JM, Yusuf S, Young J, et al. Prevention of heart failure in patients in the heart outcomes prevention evaluation (HOPE) study. Circulation 2003; 107: 1284-1290. Go to original source... Go to PubMed...
  6. MERIT - HF Investigators. Effect of metoprolol CR/XL in chronic heart failure. Lancet 1999; 353: 2001-2007. Go to original source...
  7. Poole - Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European trial (COMET). Lancet 2003; 362: 7-13. Go to original source... Go to PubMed...
  8. Cohn JN, Tognoni A. A randomized trial of the angiotensin - receptor blocker valsartan in chronic heart failure. N Engl. J Med 2001; 345: 1667-1675. Go to original source... Go to PubMed...
  9. Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001; 103: 2668-2673. Go to original source... Go to PubMed...
  10. Held C, Gerstein HC, Yusuf S, et al. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation 2007; 115: 1371-1375. Go to original source... Go to PubMed...
  11. Jaffe AS, Spadaro JJ, Schechtman K, et al. Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus. Am Heart J 1984; 108: 31-37. Go to original source... Go to PubMed...
  12. Aguilar D, Solomon SD, Kober L, et al. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation 2004; 110: 1572-1578. Go to original source... Go to PubMed...
  13. Das SR, Drazner MH, Yancy CW, et al. Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the studies of left ventricular dysfunction (SOLVD) prevention trial. Am Heart J; 2004; 148: 883-888. Go to original source... Go to PubMed...
  14. Domanski M, Krause-Steinrauf H, Deedwania P, et al. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol 2003; 42: 914-922. Go to original source... Go to PubMed...
  15. From AM, Leibson CL, Bursi F, et al. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med 2006; 119, 591-599. Go to original source... Go to PubMed...
  16. Hellerman JP, Jacobsen SJ, Gersh BJ, et al. Heart failure after myocardial infarction: a review. Am J Med 2002; 113: 324-330. Go to original source... Go to PubMed...
  17. Gustaffson I, Brendorp B, Seibaek M, et al. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol 2004; 43: 771-777. Go to original source... Go to PubMed...
  18. Pijna IL, Buchter C. Heart failure in women. Cardiol Rev 2003; 11: 337-344. Go to original source... Go to PubMed...
  19. Murarka S, Movahed MR. Diabetic cardiomyopathy. J Card Fail 2010; 16: 971-979. Go to original source... Go to PubMed...
  20. Saunders J, Mathewkutty S, Drazner MH, MGuire DK: Cardiomyopathy in type 2 diabetes: update on pathophysiological mechanisms. Herz 2008; 33: 184-190. Go to original source... Go to PubMed...
  21. Orasanu G, Plutzky J: The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol 2009; 53: S35-S42. Go to original source... Go to PubMed...
  22. Rask-Madsen C, King GL: Mechanisms of disease: Endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 2007; 3: 46-56. Go to original source... Go to PubMed...
  23. Khera A, Mc Guire DK: Management of diabetic dyslipidemia: need for reappraisal of the goals. Am J Cardiovasc Drugs 2005; 5: 83-91. Go to original source... Go to PubMed...
  24. Mathewkutty S, McGuire DK: Platelet perturbations in diabetes: Implications for cardiovascular disease risk and treatment. Expert Rev Cardiovasc Ther 2009; 7: 541-549. Go to original source... Go to PubMed...
  25. Libby P, Plutzky J: Inflammation in diabetes mellitus: Role of peroxisome proliferator-activated receptor alpha and peroxisome proliferator-activated receptor-gamma agonists. Am J Cardiol 2007; 99: 27B-40B. Go to original source... Go to PubMed...
  26. Lindsey JB, Cipollone F, Abdullah SM, McGuire DK: Receptor for advanced glycation end-poducts (RAGE). Cardiovascular implications. Diab Vasc Dis Res 2009; 6: 7-14. Go to original source... Go to PubMed...
  27. Bertoni AG, Tsai A, Kasper EK, et al. Diabetes and idiopathic cardiomyopathy: a nationwide case-control study. Diabetes Care 2003; 26: 2791-2795. Go to original source... Go to PubMed...
  28. Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation 2007; 116: 434-448. Go to original source... Go to PubMed...
  29. Poormina IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circulation 2006; 98: 596-605. Go to original source... Go to PubMed...
  30. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007; 115: 3213-3223. Go to original source... Go to PubMed...
  31. Masoudi FA, Inzucchi SE. Diabetes mellitus and heart failure: epidemiology, mechanisms and pharmacotherapy. Am J Cardiol 2006; 99(suppl. 1): 113-132. Go to original source... Go to PubMed...
  32. Cai L, Wang Y, Zhou G, et al. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J Am Coll Cardiol 2006; 48: 1688-1697. Go to original source... Go to PubMed...
  33. Wang J, Song Y, El-Sherif L, et al. Cardiac metallothionein induction plays the major roll in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation 2006; 113: 544-554. Go to original source... Go to PubMed...
  34. Kass DA. Getting better without AGE: new insights into the diabetic heart. Circ Res 2003; 92: 704-706. Go to original source... Go to PubMed...
  35. Cesario DA, Braz R, Shivkumar K. Alterations in ion channel physiology in diabetic cardiomyopathy. Endocrinol Metab Clin Nort Amer 2006; 35: 601-610. Go to original source... Go to PubMed...
  36. Yan SF, Ramasamy R, Naka Y, et al. Glycation, inflamation and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003; 93: 1159-1169. Go to original source... Go to PubMed...
  37. Lim SH, Mac Fayden RJ, Lip GYH. Diabetes mellitus, the renin-angiotensin-aldosterone system and the heart. Arch Intern Med 2004; 164: 1737-1748. Go to original source... Go to PubMed...
  38. Noguchi T, Hunlich M, Camp PC, et al. Thin filament-based modulation of contractile performance in human heart failure. Circulation 2004; 110: 982-987. Go to original source... Go to PubMed...
  39. Shigegawa M, Katanosaka Y, Wakabayashi S. Regulation of the cardiac Na+/Ca+2 exchanger by calcineurin and protein kinase C. Ann NY Acad Sci 2007; 1099: 53-63. Go to original source... Go to PubMed...
  40. Flesch M, Margulies KB, Mochmann HC, et al. Differential regulation of mitogen-activated protein kinases in the failing human heart in response to mechanical unloading. Circulation 2001; 104: 2273-2276. Go to original source... Go to PubMed...
  41. Zhburn YT, Grayburn P, Karim A. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 2000; 97: 1784-1789. Go to original source... Go to PubMed...
  42. Barouch LA, Berkowitz DE, Harrison RW, et al. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 2003; 108: 754-759. Go to original source... Go to PubMed...
  43. Kuethe F, Sigusch HH, Bornstein SR, et al. Apoptosis in patients with dilated cardiomyopathy and diabetes: a feature of diabetic cardiomyopathy? Horm Metab Res 2007; 39: 672-676. Go to original source... Go to PubMed...
  44. Iacobellis G, Ribando MC, Zappaterreno A, et al. Relationship of insulin sensitivity and left ventricular mass in uncomplicated obesity. Obes Res 2003; 11: 518-524. Go to original source... Go to PubMed...
  45. Morisco C, Condorelli G, Trimarco V, et al. Akt mediates the cross-talk between beta-adrenergic and insulin receptors in neonatal cardiomyocytes. Circ Res 2005; 96: 180-188. Go to original source... Go to PubMed...
  46. Wang CC, Goalstone ML, Drazuin B. Molecular mechanisms of insulin resistance that impact cardiovascular biology. Diabetes 2004; 53: 2735-2740. Go to original source... Go to PubMed...
  47. Villarreal FJ, Kim NN, Ungab GD, et al. Identification of functional angiotensin II receptors on rat cardiac fibroblasts. Circulation 1993; 88: 2849-2861. Go to original source... Go to PubMed...
  48. Dostal DE, Baker KN. The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res 1999; 85: 643-650. Go to original source... Go to PubMed...
  49. Greenberg B, Quinones MA, Koilpillai C, et al. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 1955; 91: 2573-2581. Go to original source... Go to PubMed...
  50. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772-776. Go to original source... Go to PubMed...
  51. Mulieri LA, Leavitt BJ, Hasenfuss G, et al. Contraction frequency dependence of twich and diastolic tension in human dilated cardiomyopathy. Basic Res Cardiol 1992; 87(suppl 1): 199-212. Go to original source... Go to PubMed...
  52. Szczepaniak LS, Victor RG, Orci L, et al. Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America. Circ Res 2007; 101: 759-767. Go to original source... Go to PubMed...
  53. Galderisi M. Diastolic dysfunction and diabetic cardiomyopathy: evaluation by doppler echocardiography. J Am Coll Cardiol 2006; 48: 1548-1551. Go to original source... Go to PubMed...
  54. Poirier P, Bogaty P, Philippon F, et al. Preclinical diabetic cardiomyopathy: relation of left ventricular diastolic dysfunction to cardiac autonomic neuropathy in men with uncomplicated well-controlled type 2 diabetes. Metabolism 2003; 52: 1056-1061. Go to original source... Go to PubMed...
  55. Diamant M, Lamb HJ, Groeneveld Y, et al. Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 2003; 42: 328-335. Go to original source... Go to PubMed...
  56. Berg TJ, Snorgaard O, Faber J, et al. Serum levels of advanced glycation end-products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care 1999; 22: 1186-1190. Go to original source... Go to PubMed...
  57. Bertoni AG, Goff DC jr, D´Agostino RB jr. Diabetic cardiomyopathy and subclinical cardiovascular disease: the: multi-ethnic study of atherosclerosis (MESA). Diabetes Care 2006; 29: 588-594. Go to original source... Go to PubMed...
  58. McMurray JJV, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and Treatment of acute and chronic heart failure 2012. Eur J Heart Fail 2012; 14: 803-869. Go to original source... Go to PubMed...
  59. Swedberg K, Komajda M, Boehm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-885. Go to original source... Go to PubMed...
  60. Packer M, Coats AJ, Fowler MF, et al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl J Med 2001; 344: 1651-1658. Go to original source... Go to PubMed...
  61. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717. Go to original source... Go to PubMed...
  62. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321. Go to original source... Go to PubMed...
  63. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS). Lancet 1998; 352: 854-865. Go to original source...
  64. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572. Go to original source... Go to PubMed...
  65. The Action to Control CardiOvascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2553. Go to original source... Go to PubMed...
  66. Eshaghian S, Horwich TB, Fonarow GC. An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. Am Heart J 2006; 151: 91-98. Go to original source... Go to PubMed...
  67. Nichols GA, Koro CE, Gullion CM, et al. The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev 2005; 21: 51-57. Go to original source... Go to PubMed...
  68. Smoke S, Horwich TB, Fonarow GC. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J 2005; 149: 168-174. Go to original source... Go to PubMed...
  69. Massoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin and outcomes in older patients with diabetes and heart failure. Circulation 2005; 111: 583-590. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.